Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: Vitamin Shoppe, Walgreen/Rite Aid, BioPharmX

This article was originally published in The Tan Sheet

Executive Summary

FTC requests more from Walgreen, Rite Aid; SDC manufactures for Axxess; Human Roots expands online sales; and more news in brief.

You may also be interested in...



Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers

Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

With One Launch Under Way, SpringWorks Ramps Up For A Second

The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108074

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel